Cytosorbents (CTSO) Capital Expenditures Growth (3y) (2014 - 2026)
Powered by 
Analysis
Cytosorbents (CTSO) Capital Expenditures Growth (3y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | -0.66% |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | -14.20% |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 12.42% |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 9.94% |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 10.89% |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 11.78% |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | 6.38% |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 12.81% |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 9.52% |
| 10 | Cytosorbents | 20.00 Mn | 15.59 Mn | 7.05 Mn | 27.38% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27.38% |
| Mar 31, 2026 | -72.16% |
| Dec 31, 2025 | -20.31% |
| Sep 30, 2025 | -70.16% |
| Jun 30, 2025 | -27.43% |
| Mar 31, 2025 | -50.89% |
| Dec 31, 2024 | -64.42% |
| Sep 30, 2024 | -44.55% |
| Jun 30, 2024 | -71.73% |
| Mar 31, 2024 | -52.76% |
| Dec 31, 2023 | -16.15% |
| Sep 30, 2023 | -14.76% |
| Jun 30, 2023 | -66.15% |
| Mar 31, 2023 | 29.34% |
| Dec 31, 2022 | 14.89% |
| Sep 30, 2022 | 71.71% |
| Jun 30, 2022 | 181.72% |
| Mar 31, 2022 | 94.01% |
| Dec 31, 2021 | 105.55% |
| Sep 30, 2021 | 220.83% |